FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

541 letters match. Newest first.

  1. ibeautistore.com

    ibeautistore.com sold Umary hyaluronic acid capsules as a supplement, but FDA found hidden diclofenac, dexamethasone, and omeprazole.

    High risk
  2. Intelligent Remedies, Inc.

    FDA warned Intelligent Remedies that disease-treatment claims make nine products unapproved new drugs.

    High risk
  3. Diamond-Herpanacine of PA, Inc.

    FDA says Diamond-Herpanacine supplement claims make its eye and skin products unapproved drugs.

    Low
  4. Supersmart USA, LLC

    FDA says Supersmart USA sold dietary supplements with disease-treatment claims, making them unapproved and misbranded drugs.

    Low
  5. Beauty of Aztlan LLC

    FDA warns Beauty of Aztlan it sells unapproved, misbranded injectable botulinum toxin drugs online to U.S. consumers.

    High risk
  6. Dry Springs Pharmacy

    FDA warned Dry Springs Pharmacy that its website sells unapproved and misbranded opioids, benzodiazepines, and stimulants to U.S. consumers.

    High risk
  7. Half Hill Farm Inc.

    FDA cited Half Hill Farm's mushroom extracts as unapproved new drugs over website disease-treatment claims.

    Low
  8. Gram Peptides

    Gram Peptides sold unapproved injectable peptide drugs and bacteriostatic water online as new drugs, FDA says.

    High risk
  9. FormPour

    FDA warned FormPour over selling an unapproved new drug, SMGT-GLT-1 Nano Microneedle Patch, on eBay.

    High risk
  10. Citra100mg

    FDA warns Citra100mg it sells unapproved, misbranded tramadol opioids without prescriptions to U.S. consumers online.

    High risk
  11. Premium Health Management Inc. dba Premium Health

    FDA warns Premium Health over misleading website claims for compounded semaglutide and tirzepatide.

    Low
  12. Lean Rx, Inc. dba SkinnyRx

    SkinnyRx's website misbranded compounded semaglutide and tirzepatide by wrongly suggesting it makes the drugs and that they are FDA-approved.

    Low
  13. Kare Solutions, LLC dba Zappy

    FDA warned Zappy that its website falsely suggested it compounds semaglutide, tirzepatide, and liraglutide and made misleading approval-like claims.

    Low
  14. Strut Health, LLC dba Strut

    FDA says Strut Health's website falsely labeled compounded semaglutide and tirzepatide as its own and FDA-approved.

    Low
  15. Refills Health, LLC dba Refills Health

    FDA told telehealth seller Refills Health its website misbrands compounded semaglutide by implying FDA approval and naming itself as maker.

    Medium
  16. Viv Health, Inc. dba VIV RX

    FDA warned telehealth company VIV RX that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.

    Medium
  17. Peaks Curative, LLC dba Peaks

    FDA warned Peaks Curative over false or misleading website claims for compounded (pharmacy-made) semaglutide, including implied FDA approval.

    Low
  18. PharmaZee

    FDA warns PharmaZee over misleading website claims for compounded semaglutide and tirzepatide, including implying PharmaZee compounds them and that they are proven.

    Low
  19. Join Josie

    FDA says Join Josie's website misbranded compounded semaglutide and tirzepatide by falsely implying FDA approval and naming Join Josie as compounder.

    Low
  20. Kin Meds

    FDA warned Kin Meds over false claims for compounded semaglutide and tirzepatide, including implying it is the compounder and that products are approved.

    Low
  21. Levity Inc. dba Levity

    FDA warned Levity over misleading website claims for compounded semaglutide and liraglutide, including implying Levity made the drugs and that they were FDA-approved.

    Low
  22. Better Health Labs, Inc. dba Measured

    FDA warned telehealth seller Measured its website misbranded compounded semaglutide and tirzepatide by implying it made them and that they were FDA-approved.

    Medium
  23. MEDVi, LLC dba MEDVi

    FDA says telehealth seller MEDVi misbranded compounded semaglutide and tirzepatide by implying MEDVi makes them and that they are FDA-approved.

    Medium
  24. NewSelf Limited dba NewSelf

    FDA warns NewSelf over misleading website claims for compounded semaglutide and tirzepatide, including false compounder and FDA-approval implications.

    Low
  25. 24HrDoc, Inc. dba 24HrDoc

    FDA says 24HrDoc's website misbrands compounded semaglutide and tirzepatide with false claims that it compounds them and that they match Ozempic, Wegovy, Mounjaro, Zepbound.

    Medium
  26. Alan Health Technologies Inc. dba Alan

    FDA warns Alan Health Technologies over website falsely labeling compounded semaglutide and tirzepatide as Alan-made.

    Low
  27. Dripgym Mobile Parent, LLC dba Amp Health

    FDA warned Amp Health that its website misbranded compounded semaglutide and tirzepatide with false maker and approval-implying claims.

    Low
  28. Belle Health LLC dba Belle

    FDA warned Belle Health that its website falsely suggests Belle compounds semaglutide and tirzepatide, making the drugs misbranded.

    Low
  29. Bliv Wellness LLC dba Bliv

    FDA warns Bliv Wellness that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.

    Medium
  30. BluefitMD

    FDA warned BluefitMD that its website falsely labels compounded semaglutide and tirzepatide as its own and as FDA-approved.

    Low
  31. Deluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics

    FDA warned Deluxe IV and Aesthetics over misleading website claims for compounded semaglutide and tirzepatide, including implying FDA approval.

    Low
  32. Aspen Aesthetics dba Fifty 410

    FDA warns Fifty 410 over misleading website claims for compounded semaglutide and tirzepatide, including implied compounding and 'clinically proven' claims.

    Low
  33. Genesis Health International Inc. dba Genesis

    FDA warns Genesis over misleading website claims for compounded semaglutide and tirzepatide.

    Low
  34. Dynamic Stem Cell Therapy

    FDA warned Dynamic Stem Cell Therapy that its umbilical cord-derived stem cell product is an unapproved, unlicensed, misbranded biological drug.

    High risk
  35. Elanco Animal Health USA

    FDA says Elanco's Pradalex ads misbrand the livestock antibiotic by claiming first-line use and "all relevant pathogen" coverage.

    Medium
  36. Atomix LLC

    FDA warned Atomix LLC that its website sells unapproved SARM drugs MK-2866 and RAD-140 as new drugs without approval.

    High risk
  37. King Farm

    King Farm's horse feed held fumonisin up to 36.1 ppm; FDA ties it to at least 30 horse deaths.

    High risk
  38. Early to Bed, Inc.

    FDA warned Early to Bed, Inc. that its breast binders are misbranded because the manufacturer was not registered or listed with FDA.

    Low
  39. Philadelphia 7, Inc d/b/a Passional Boutique

    FDA says Philadelphia 7 sold unregistered, unlisted breast binders, making them misbranded devices.

    Low
  40. Bedner Growers, Inc.

    FDA: Bedner Growers' cucumbers tied to Salmonella outbreaks; packing line and product tested positive.

    High risk
  41. Target Corporation

    FDA warns Target that recalled ByHeart infant formula tied to an infant botulism outbreak stayed on store shelves in 20 states.

    High risk
  42. Walmart, Inc.

    Walmart kept recalled ByHeart infant formula on shelves in 21 states after a botulism outbreak recall, FDA says.

    High risk
  43. The Kroger Company

    FDA warned Kroger that recalled ByHeart infant formula tied to an infant botulism outbreak stayed on its store shelves.

    High risk
  44. Celularity, Inc

    FDA warns Celularity that Interfyl is an unapproved new drug and unlicensed biological product marketed for orthopedic and wound uses.

    High risk
  45. Handelnine Global, LLC dba Navafresh

    Navafresh sells unapproved Ayurvedic drugs online, and its Rheumacare Capsules contain about 7,000 times the lead level of concern.

    High risk
  46. Sinsin Pharmaceutical Co., Ltd.

    FDA warned Sinsin Pharmaceutical that two Korean topical pain relievers sold in the US are unapproved and misbranded drugs.

    High risk
  47. Korea Filler Experts

    FDA warned Korea Filler Experts that its website sells unapproved and misbranded injectable botulinum toxin drugs, including Nabota 100UI, to U.S. consumers.

    High risk
  48. Cosmenic

    FDA warned Panama-based Cosmenic that its website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers.

    High risk
  49. Dermacare dba Filler Outlet

    South Korea's Dermacare, doing business as Filler Outlet, sells unapproved, misbranded injectable botulinum toxin to U.S. consumers through its website.

    High risk
  50. Maypharm

    Maypharm website sells unapproved, misbranded Botulax botulinum toxin to U.S. consumers, FDA says.

    High risk